Clinical Trials at Moffitt Cancer Center
As of August 2026, 272 paid clinical trials are recruiting at Moffitt Cancer Center, located at 12902 USF MAGNOLIA DR, TAMPA, FL 33612-9416, phone (813) 745-3862 in Tampa, Florida. Active studies at this site cover conditions such as Breast Cancer, Heart Failure and Colorectal Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Tampa
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
276 clinical trials at Moffitt Cancer Center
·Clear filters·A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Common conditions studied in Tampa
- Breast Cancer (22 active studies)
- Heart Failure (16 active studies)
- Colorectal Cancer (15 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Cancer (13 active studies)
- Myelodysplastic Syndromes (12 active studies)
Leading research sponsors in Tampa
- H. Lee Moffitt Cancer Center and Research Institute
- University of South Florida
- AstraZeneca
- National Cancer Institute (NCI)
- Eli Lilly and Company
Frequently asked questions
How many paid clinical trials are currently recruiting in Tampa?
There are approximately 1,048 recruiting clinical trials in Tampa, Florida listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Tampa pay participants?
Most recruiting trials in Tampa compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Tampa?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Tampa?
The most common conditions under active study in Tampa include Breast Cancer (22), Heart Failure (16), Colorectal Cancer (15), Acute Myeloid Leukemia (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Tampa?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Tampa on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Tampa?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Tampa?
Recruiting research sites in Tampa include Moffitt Cancer Center, University of South Florida, Tampa General Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Tampa right now?
The largest active categories in Tampa are Cancer & tumors (378), Neurology & pain (63), Cardiovascular (54). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Moffitt Cancer Center?
Moffitt Cancer Center is located at 12902 USF MAGNOLIA DR, TAMPA, FL 33612-9416. Use the Google Maps link in the intro above to get directions.
How do I contact Moffitt Cancer Center?
You can reach Moffitt Cancer Center by phone at (813) 745-3862. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.